SGLT2 Inhibitors May Lead to Better Kidney Outcomes Than GLP-1 Drugs

Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of adverse kidney outcomes than glucagon-like peptide-1 (GLP-1) receptor agonists in people with type 2 diabetes in a recent study that emulated a clinical trial.